XML 31 R13.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Stock Incentive Plan | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-based Payment Arrangement [Abstract] |
Stock Incentive Plan | Stock Incentive Plan Stock Incentive Plan The Company recorded share-based compensation expense as follows for the years ended December 31, 2021, 2020 and 2019:
| Years Ended
| December 31, 2021 |  | December 31, 2020 |  | December 31, 2019
Salaries, wages and employee benefits - continuing operations | $ | 9,108 |  |  | $ | 9,715 |  |  | $ | 10,595 |
Salaries, wages and employee benefits - discontinued operation | 16 |  |  | 85 |  |  | 179 |
Total share-based compensation expense | $ | 9,124 |  |  | $ | 9,800 |  |  | $ | 10,774 |
In May 2016, the Company adopted the 2016 Omnibus Incentive Compensation Plan (the “Omnibus Plan”) for the issuance of up to 2,000 common shares. As of December 31, 2021, approximately 801 shares remain available for grant under the Omnibus Plan. Stock Options Certain executives are eligible to receive grants of stock options. Employees may exercise the stock options at anytime after the grant is vested but no later than seven years after the date of grant. Stock options vest over a three-year period from the date of grant. For stock option awards, under the Plan, the exercise price is equal to the price of the Company’s common stock on the date of grant. Share-based compensation expense associated with these awards is amortized ratably over the vesting period. The Company estimated the fair value of the grants using the Black-Scholes option-pricing model. The weighted average grant-date fair value of the stock option awards granted under the Plan and the weighted average assumptions under the Black-Scholes option-pricing model were as follows for the years ended December 31, 2021 and 2020. The Company did not grant stock options during the year ended December 31, 2019.
| December 31, 2021 |  | December 31, 2020 |  |
Weighted average grant-date fair value | $ | 18.36 |  |  | $ | 14.79 |  |  |
Weighted average assumptions under Black-Scholes option model: |  |  |  |  |
Expected dividend yield | 1.1 | % |  | 1.1 | % |  |
Expected stock price volatility | 28.9 | % |  | 24.1 | % |  |
Risk-free interest rate | 0.6 | % |  | 1.5 | % |  |
Expected life of awards (years) | 5.8 |  | 5.9 |  |
Stock option transactions during the year ended December 31, 2021 on a continuing operations basis were as follows:
| Number of Shares |  | Weighted Average Exercise Price
Outstanding as of January 1 | 359 |  |  | $ | 55.79 |
Granted | 39 |  |  | 75.05 |
Exercised | (56) |  |  | 53.91 |
Forfeited or Canceled | — |  |  | — |
Outstanding as of December 31 | 342 |  |  | $ | 58.44 |
As of December 31, 2021, the weighted average remaining contractual life of stock options both outstanding and exercisable was approximately three years. The total fair value of stock options vested during 2021, 2020, 2019 was $922, $1,377, and $1,887, respectively. As of December 31, 2021, the total share-based compensation expense related to unvested stock options not yet recognized was $695, and the weighted average period over which it is expected to be recognized is approximately two years. The following table sets forth the exercise price range, number of shares, weighted average exercise price and remaining contractual lives by groups of similar price on a continuing operations basis as of December 31, 2021:
|  |  |  | Stock Options Outstanding |  | Stock Options Exercisable
Range of Exercise Prices |  | Number of Shares |  | Weighted Average Remaining Contractual Life (in years) |  | Weighted Average Exercise Price |  | Exercisable as of December 31, 2021 |  | Weighted Average Exercise Price
$ | 43.67 |  | - | $ | 47.82 |  |  | 107,403 |  |  | 1.6 |  | $ | 45.87 |  |  | 107,403 |  |  | $ | 45.87 |
50.71 |  | - | 59.89 |  |  | 56,689 |  |  | 2.0 |  | 55.66 |  |  | 56,689 |  |  | 55.66 |
60.42 |  | - | 65.96 |  |  | 139,309 |  |  | 4.0 |  | 64.60 |  |  | 103,391 |  |  | 64.13 |
$ | 75.05 |  | - | $ | 75.05 |  |  | 39,139 |  |  | 6.1 |  | 75.05 |  |  | — |  |  | — |
|  |  |  | 342,540 |  |  |  |  | $ | 58.44 |  |  | 267,483 |  |  | $ | 55.01 |
As of December 31, 2021, the total intrinsic value of outstanding and exercisable stock options was $21,459 and $17,677, respectively. The total intrinsic value of stock options exercised during 2021, 2020 and 2019 was $2,137, $1,568 and $2,196, respectively. Stock option transactions during the year ended December 31, 2021 on a discontinued operation basis were as follows:
| Number of Shares |  | Weighted Average Exercise Price
Outstanding as of January 1 | 14 |  | $ | 52.15 |
Granted | — |  | — |
Exercised | (14) |  | 52.15 |
Forfeited or Canceled | — |  | — |
Outstanding as of December 31 | — |  | $ | — |
The total fair value of stock options vested during 2020 and 2019 was $58, and $56, respectively. There were no stock options vested during 2021.The total intrinsic value of stock options exercised during 2021 and 2019 was $458, and $193, respectively. There were no stock options exercised during 2020. Restricted Shares The Company’s primary long-term incentive plan is a restricted share award plan that entitles employees to receive a share of the Company’s common stock subject to vesting requirements based on continued employment. Shares granted under the restricted share award plan are restricted from sale or transfer until vesting, and the restrictions lapse in three equal installments beginning one year after the date of grant. Dividends are paid in cash on a current basis throughout the vesting period. Share-based compensation expense associated with these awards is amortized ratably over the requisite service period. All forfeitures are recognized as incurred. Restricted share transactions on a continuing operations basis for the year ended December 31, 2021 were as follows:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Outstanding as of January 1 | 213 |  |  | $ | 62.78 |
Granted | 109 |  |  | 75.35 |
Vested | (110) |  |  | 61.77 |
Forfeited | (21) |  |  | 69.08 |
Outstanding as of December 31 | 191 |  |  | $ | 69.84 |
The weighted average grant-date fair value of the restricted shares granted under the Plan during the years ended December 31, 2021, 2020 and 2019 were $75.35, $65.88 and $59.49, respectively. The total fair value of restricted shares that vested during 2021, 2020 and 2019 was $8,487, $9,180, and $7,684, respectively. As of December 31, 2021, the total share-based compensation expense related to restricted shares not yet recognized was $7,794, and the weighted average period over which it is expected to be recognized is approximately two years. Restricted share transactions on a discontinued operation basis for the year ended December 31, 2021 were as follows:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Outstanding as of January 1 | 8 |  |  | $ | 60.83 |
Granted | — |  |  | — |
Vested | (4) |  |  | 60.54 |
Forfeited | (4) |  |  | 63.62 |
Outstanding as of December 31 | — |  |  | $ | — |
The weighted average grant-date fair value of the restricted shares granted under the Plan during the years ended December 31, 2020 and 2019 were $63.24 and $59.07, respectively. The total fair value of restricted shares that vested during 2021, 2020 and 2019 was $364, $625, and $270, respectively. Performance Shares Certain executives and key employees are eligible to receive grants of performance awards. The performance share agreement provides for awards based on achieving certain financial targets, such as targets for earnings before interest, taxes, depreciation and amortization, and the Company’s total shareholder return as compared to the total shareholder return of a selected peer group, as determined by the Company’s Board of Directors. Performance targets are set at the beginning of each three-year measurement period. The share awards are earned over the vesting period, and the number of shares earned is determined based on the cumulative results for the measurement period. The performance agreement provides for employees to earn —% to 200% of the target awards depending on the actual performance achieved, with no shares earned if performance is below the established minimum target. Performance shares do not receive dividends until the shares are vested. Awards earned are paid in shares of common stock of the Company at the end of the vesting period. Share-based compensation expense associated with these awards is amortized ratably over the vesting period. Depending on the financial target, share-based compensation expense is determined based on the projected assessment of the level of performance that will be achieved. All forfeitures are recognized as incurred. The grant-date fair value of performance shares granted with a financial target based on the Company’s total shareholder return was estimated using a Monte Carlo simulation model. The weighted average grant-date fair value of performance awards granted under the Plan and the weighted average assumptions under the Monte Carlo simulation model were as follows for the years ended December 31, 2021, 2020 and 2019:
| Year Ended
| December 31, 2021 |  | December 31, 2020 |  | December 31, 2019
Weighted average grant-date fair value | $ | 87.33 |  |  | $ | 69.15 |  |  | $ | 61.42 |
Weighted average assumptions under the Monte Carlo simulation model: |  |  |  |  |
Expected stock price volatility | 34.5 | % |  | 23.5 | % |  | 23.4 | %
Weighted average risk-free interest rate | 0.2 | % |  | 1.4 | % |  | 2.5 | %
Performance award transactions for the year ended December 31, 2021 on a continuing operations basis were as follows assuming target levels of performance:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Outstanding as of January 1 | 65 |  |  | $ | 67.62 |
Granted | 36 |  |  | 87.33 |
Earned | (11) |  |  | 72.30 |
Forfeited or unearned | (11) |  |  | 70.22 |
Outstanding as of December 31 | 79 |  |  | $ | 75.61 |
As of December 31, 2021, the total share-based compensation expense related to unearned performance awards not yet recognized, assuming the Company’s current projected assessment of the level of performance will be achieved, was $3,618, and the weighted average period over which it is expected to be recognized is approximately two years. The excess tax benefit realized for tax deductions in the United States related to the exercise of stock options, vesting of restricted stock and vesting of performance awards under the Pl an was $911, $2,340, and $2,621 for the years ended December 31, 2021, 2020 and 2019, respectively, on a continuing operations basis. The excess tax benefit realized for tax deductions in the United States related to the exercise of stock options, vesting of restricted stock and vesting of performance awards under the Plan was $95, $75, and $95 for the years ended December 31, 2021, 2020 and 2019, respectively, on a discontinued operation basis. Employee Stock Purchase Plan Under the 2005 Employee Stock Purchase Plan (the “ESPP”), the Company is authorized to issue up to a remaining 323 shares of common stock to employees. These shares may be issued at a price equal to 90% of the lesser of the market value on the first day or the last day of each six-month purchase period. Common stock purchases are paid for through periodic payroll deductions and/or up to two lump sum contributions. Employee stock purchase plan activity and related information was as follows on a continuing operations basis:
| Year Ended
| December 31, 2021 |  | December 31, 2020 |  | December 31, 2019
Shares purchased by participants under the ESPP | 12 |  |  | 14 |  |  | 11 |
Average purchase price | $ | 75.71 |  |  | $ | 44.24 |  |  | $ | 51.50 |
Weighted average fair value of each purchase under the ESPP granted 1 | $ | 30.68 |  |  | $ | 20.99 |  |  | $ | 13.68 |
Share-based compensation expense for ESPP | $ | 369 |  |  | $ | 292 |  |  | $ | 150 |
1 Equal to the discount from the market value of the common stock at the end of each six month purchase period
Employee stock purchase plan activity and related information was as follows on a discontinued operation basis:
| Year Ended
| December 31, 2021 |  | December 31, 2020 |  | December 31, 2019
Shares purchased by participants under the ESPP | — |  |  | 1 |  |  | 1 |
Average purchase price | $ | — |  |  | $ | 44.35 |  |  | $ | 51.39 |
Weighted average fair value of each purchase under the ESPP granted 1 | $ | — |  |  | $ | 18.11 |  |  | $ | 13.48 |
Share-based compensation expense for ESPP | $ | — |  |  | $ | 20 |  |  | $ | 13 |
1 Equal to the discount from the market value of the common stock at the end of each six month purchase period
Director Restricted Shares Under the Amended and Restated Non-Employee Director Stock Plan (the “Amended Plan”), approved in May 2007 and further amended in February 2013 and January 2016, up to 360 common shares may be issued. As of December 31, 2021, approximately 75 shares remain available for grant under the Amended Plan. Under the Amended Plan, each non-employee director receives an annual grant of restricted shares of the Company’s common stock. The restricted shares vest on the earlier of (a) the day immediately prior to the first annual shareholder meeting that occurs after the grant date or (b) one year after the grant date. Each director may elect to defer receipt of the common shares until the director departs from the Company’s Board of Directors. If a director elects to defer receipt, the Company will issue deferred stock units in which the director does not have voting rights or other incidents of ownership until the shares are issued. Each deferred stock unit is eligible for a dividend equivalent in the form of additional restricted stock units for each cash dividend paid by the Company. Director restricted share transactions for the year ended December 31, 2021 were a s follows:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Outstanding as of January 1 | 24 |  |  | $ | 42.88 |
Granted | 17 |  |  | 93.39 |
Vested | (26) |  |  | 47.12 |
Forfeited | — |  |  | — |
Outstanding as of December 31 | 15 |  |  | $ | 93.46 |
| Year Ended
| December 31, 2021 |  | December 31, 2020 |  | December 31, 2019
Share-based compensation expense for restricted shares | $ | 1,436 |  |  | $ | 1,026 |  |  | $ | 970 |
Excess tax benefit for the vesting of restricted shares | $ | 342 |  |  | $ | 253 |  |  | $ | 244 |
The total fair value of restricted shares that vested during 2021, 2020 and 2019 was $2,514, $771, and $970, respectively. As of December 31, 2021, the total share-based compensation expense related to the restricted shares not yet recognized was $527, and the weighted average period over which it is expected to be recognized is less than one year.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration